AIDS-Related Opportunistic Infections

Subscribe to Selected New Research on AIDS-Related Opportunistic Infections

41 relevant articles (7 outcomes, 1 trials/studies) found for this Disease

Description: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.

Also Known As:

AIDS Related Opportunistic Infections; AIDS-Related Opportunistic Infection; HIV Related Opportunistic Infections; HIV-Related Opportunistic Infection; Infection, HIV-Related Opportunistic; Infections, HIV-Related Opportunistic; Opportunistic Infection, AIDS-Related; Opportunistic Infection, HIV-Related; Opportunistic Infections, AIDS Related; Opportunistic Infections, HIV Related; HIV-Related Opportunistic Infections; Opportunistic Infections, AIDS-Related; Opportunistic Infections, HIV-Related

Relationship Network

Disease Context: Research Results

Bacterial Infections and Mycoses

Infection: 225242

Opportunistic Infections: 2140

Virus Diseases: 1376

Opportunistic Infections: 2140

RNA Virus Infections: 46

Retroviridae Infections: 200

Lentivirus Infections: 47

HIV Infections: 10776

Parasitic Diseases: 561

Opportunistic Infections: 2140

Immune System Diseases: 1319

Immunologic Deficiency Syndromes: 70

HIV Infections: 10776

Related Diseases

1.	Acquired Immunodeficiency Syndrome (AIDS)
2.	Opportunistic Infections (Opportunistic Infection)
3.	Tuberculosis
4.	Bacterial Infections (Bacterial Infection)
5.	Hepatitis

Experts

1.	de Waal, J: 1 article (11/2007)
2.	Dreyer, W P: 1 article (11/2007)
3.	Bruno, Raffaele: 1 article (04/2003)
4.	Filice, Gaetano: 1 article (04/2003)
5.	Sacchi, Paolo: 1 article (04/2003)
6.	Boelaert, J R: 1 article (03/2001)
7.	Grosset, J: 1 article (03/2001)
8.	Lounis, N: 1 article (03/2001)
9.	Tognazioli, C: 1 article (03/2001)
10.	Gomes, M S: 1 article (03/2001)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to AIDS-Related Opportunistic Infections:

1.	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/01/2005 - "In this paper, we describe an aminopyrimidinimino isatin lead compound as a novel non-nucleoside reverse transcriptase inhibitor with broad-spectrum chemotherapeutic properties for the effective treatment of AIDS and AIDS-related opportunistic infections. " 05/01/2005 - "HIV is the most significant risk factor for many opportunistic infections like tuberculosis, bacterial infections etc. In this paper, we designed aminopyrimidinimino isatin lead compound as a novel non-nucleoside reverse transcriptase inhibitor with broad-spectrum chemotherapeutic properties for the effective treatment of AIDS and AIDS-related opportunistic infections. " 11/15/2004 - "HIV is the most significant risk factor for many opportunistic infections like tuberculosis, hepatitis, bacterial infections, etc. In this paper, we designed aminopyrimidinimino isatin lead compound as a novel non-nucleoside reverse transcriptase inhibitor with broad-spectrum chemotherapeutic properties for the effective treatment of AIDS and AIDS-related opportunistic infections. " Order ALL the reference details at left...
2.	IsatinIBA 01/01/2005 - "In this paper, we describe an aminopyrimidinimino isatin lead compound as a novel non-nucleoside reverse transcriptase inhibitor with broad-spectrum chemotherapeutic properties for the effective treatment of AIDS and AIDS-related opportunistic infections. " 05/01/2005 - "HIV is the most significant risk factor for many opportunistic infections like tuberculosis, bacterial infections etc. In this paper, we designed aminopyrimidinimino isatin lead compound as a novel non-nucleoside reverse transcriptase inhibitor with broad-spectrum chemotherapeutic properties for the effective treatment of AIDS and AIDS-related opportunistic infections. " 11/15/2004 - "HIV is the most significant risk factor for many opportunistic infections like tuberculosis, hepatitis, bacterial infections, etc. In this paper, we designed aminopyrimidinimino isatin lead compound as a novel non-nucleoside reverse transcriptase inhibitor with broad-spectrum chemotherapeutic properties for the effective treatment of AIDS and AIDS-related opportunistic infections. " Order ALL the reference details at left...
3.	Nevirapine (Viramune)FDA Link 09/01/2005 - "A series of nevirapine derivatives has been synthesized in an effort to enhance the spectrum of chemotherapeutic properties for the effective treatment of AIDS and AIDS-related opportunistic infections. " Order ALL the reference details at left...
4.	HIV ProteaseIBA 01/01/1998 - "Since potent HIV protease inhibitor drugs became widely available in early 1996, many HIV clinical specialists have noted a marked decrease in the occurrence of AIDS-related opportunistic infections, and some specialists have reported unusual clinical presentations and manifestations of previously common opportunistic infections. " Order ALL the reference details at left...
5.	Trimethoprim-Sulfamethoxazole Combination (Co-Trimoxazole)FDA LinkGeneric 08/01/2004 - "Trimethoprim-sulfamethoxazole, although not an antiretroviral drug, is extensively used for the treatment and prophylaxis of HIV-related opportunistic infections and has been associated with a significant rate of adverse reactions. " 03/01/2002 - "In industrialized countries the decision to start co-trimoxazole (CMX) prophylaxis of HIV-related opportunistic infections is based on the CD4+ cell count. " 05/01/1996 - "Most off-label drug use was for treatment and prevention of HIV-related opportunistic infections, which frequently represented the community standard of practice (e.g., trimethoprim/sulfamethoxazole for prevention of Pneumocystis carinii pneumonia), or the de facto standard of practice when no licensed therapies were available (e.g., drugs for treatment of Mycobacterium avium complex, MAC). " Order ALL the reference details at left...
6.	Protease Inhibitors (Protease Inhibitor)IBA 05/01/1998 - "Combination antiretroviral therapy with protease inhibitors has been a major contributor to a recent decline in HIV-related opportunistic infections. " 06/01/1996 - "Information about protease inhibitors and other antiretroviral drugs used to treat AIDS-related opportunistic infections is provided. " 01/01/1996 - "The list includes protease inhibitors, nucleoside analogues, and drug treatments for AIDS-related opportunistic infections and symptoms. " Order ALL the reference details at left...
7.	AntigensIBA 07/01/2008 - "Although highly active antiretroviral therapy (HAART) has strongly reduced AIDS-related opportunistic infections, the restoration and reactivation of CD4+ cells can induce an immune reconstitution inflammatory syndrome (IRIS), consisting in a deregulated inflammatory response to latent infectious pathogens and/or to their residual antigens. " 05/15/1989 - "Patients with depressed gamma-interferon production after stimulation with antigens are at a risk for AIDS-related opportunistic infections. " Order ALL the reference details at left...
8.	Anti-Retroviral Agents (Antiretroviral Agents)IBA 12/01/1997 - "New antiretroviral agents and better prophylaxis and treatment of HIV-related opportunistic infections are prolonging the lives of HIV-infected individuals. " Order ALL the reference details at left...
9.	Anti-HIV Agents (AIDS Drugs)IBA 11/01/1993 - "Research efforts to improve therapy of HIV-induced immune deficiency will involve three strategies: better anti-HIV drugs and combinations of drugs aimed at slowing the replication of HIV, immune-based therapies intended to stimulate the immune system, and multiple opportunistic pathogen prophylaxis strategies to prevent HIV-related opportunistic infections. " Order ALL the reference details at left...
10.	Essential DrugsIBA 09/01/1997 - "Most of the drugs used to treat HIV-related opportunistic infections and sexually transmitted diseases (STDs) are included on the World Health Organization's Essential Drugs List. " Order ALL the reference details at left...

Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART) 01/01/2008 - "RESULTS: HAART led to a significant reduction in the number of HIV-related opportunistic infections (P<0.0001), extended survival (61.3 versus 55.2 months; P<0.0001) and reduced hospital stays (P<0.0001) in comparison with care in the absence of HAART. " 01/01/2008 - "CONCLUSIONS: HAART is more cost-effective than treating HIV-related opportunistic infections and, contrary to conclusions drawn in developed countries, HAART is more cost-effective when the CD4+ T-cell count drops to <200 cells/mm3." 02/01/2002 - "The success of highly active antiretroviral therapy (HAART) in suppressing viral replication has led to a reduced incidence of AIDS-related opportunistic infections and this has contributed to decreased morbidity and mortality. " 07/01/2009 - "In the clinical setting, PET has been shown to allow the differentiation of AIDS-related opportunistic infections and malignancies, and to allow monitoring of side effects of HAART. " 11/01/2004 - "We review the changes in incidences of HIV-related opportunistic infections and the safety of discontinuation of primary and secondary prophylaxis for HIV-related opportunistic infections in patients achieving immune restoration after the introduction of highly active antiretroviral therapy (HAART). " Order ALL the reference details at left...
2.	Drug Therapy (Chemotherapy) 09/01/2004 - "Unfortunately, the large majority of therapeutic trials addressed to assess and compare novel antiretroviral molecules and associations, as well as studies regarding antimicrobial chemotherapy of prophylaxis of AIDS-related opportunistic infections, have just advanced age and/or underlying chronic disorders (i.e. " 02/01/1995 - "Major causes of the poor outcome were AIDS-related opportunistic infections and meningeal CNS involvement by NHL developing during or after chemotherapy. " 12/01/1986 - "Response to chemotherapy was good, but complicated by prolonged marrow suppression and development of AIDS-related opportunistic infections. " 06/01/1994 - "DATA SOURCES: English-language articles on the prevention of HIV-related opportunistic infections were identified through MEDLINE (1985 to 1993) and through review of abstracts presented at the International Conferences on AIDS, the Interscience Conferences on Antimicrobial Agents and Chemotherapy, and the National Conference on Human Retroviruses and Related Diseases. " Order ALL the reference details at left...
3.	Oral Medicine 11/01/2007 - "Oral medicine case book 3. HIV-related opportunistic infections." Order ALL the reference details at left...
4.	First Aid (Aids, First) 01/01/1997 - "Infection due to the Mycobacterium avium complex (MAC) accounts for the most frequent AIDS-related opportunistic infections, but MAC infection is usually not the first AIDS-defining event that a patient infected with HIV experiences. " Order ALL the reference details at left...
5.	Art Therapy 05/01/2009 - "Treatment guidelines have recently become more definitive regarding the optimal timing for initiation of combination antiretroviral therapy (ART) in the setting of an acute AIDS-related opportunistic infection (OI). " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on AIDS-Related Opportunistic Infections

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 7 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>